An Echo Showing HCM Is Not a Genetic Test

There is a split at the centre of this that catches people out, so here it is first. An echocardiogram showing hypertrophic cardiomyopathy is ordinary medical evidence. It is fully disclosable, and a life insurer can use it. The DNA test that finds the gene behind the same condition is a genetic result, and that is treated very differently. So when people ask how hypertrophic cardiomyopathy and life insurance fit together, the honest answer starts by separating the scan from the gene test — because the Code that protects genetic results does not protect what an echo shows.

That feels back to front. The gene test sounds more private and more predictive, and instinct says it should be the protected one while a scan is fair game. Instinct is right about the gene test and wrong about why the scan is different. An echocardiogram is not a genetic test at all, even when it is used to diagnose an inherited heart condition, and the framework that keeps genetic results off insurance applications says so in as many words.

This page explains the split, why it exists, and where it leaves you depending on whether you have a diagnosis or only a gene result.

The short answer: the scan is evidence, the gene test is not askable

Hypertrophic cardiomyopathy, or HCM, is a condition in which the heart muscle — usually the wall of the left ventricle — becomes abnormally thick. That thickening can affect how the heart pumps and how stable its rhythm is, and it is diagnosed by looking at the heart: an echocardiogram, sometimes a cardiac MRI, alongside an ECG. You can read a plain-language description of the condition from the British Heart Foundation.

Because HCM is diagnosed by imaging, the evidence of it lives in a scan report, not in a DNA result. And a scan report is ordinary medical information. If a life insurance application asks about your heart health, or a report is sought from your GP with your consent, a diagnosis of HCM and the scan findings behind it are disclosable and can be used, exactly like any other diagnosed condition. The gene test is where the special protection lives — and, as the next section shows, an echo is not one.

What the Code counts as a genetic test

The relevant framework is the Code on Genetic Testing and Insurance, an agreement between the UK Government and the Association of British Insurers. It keeps predictive genetic results off life insurance applications: insurers will not ask you to take a predictive genetic test, and they will not ask for or use the result of one.

The critical detail is what the Code means by a genetic test. It means a test that examines your DNA or chromosomes to detect an inherited variant. It expressly does not cover investigations that are not genetic tests — ECGs, echocardiograms and other scans, and blood tests such as cholesterol — even when those tests are used to detect or diagnose a condition that happens to be inherited. Those remain ordinary clinical evidence.

That exclusion is the whole reason the scan and the gene test part company. An echocardiogram detecting HCM is doing clinical work, not genetic work, in the Code's terms. It sits with the routine medical evidence an insurer can consider, not with the protected genetic results it cannot. The same logic explains why several conditions that ‘run in families’ are still fully assessable — a point drawn out in our guide to which parts of a family heart-disease history are actually testable.

An echo showing HCM is a diagnosis

Once a scan has shown HCM, you have a diagnosis, and a diagnosis is disclosable if you are asked. That covers the finding on the echo or MRI, the wall thickness measured, any ECG changes, and the clinical picture around them: symptoms such as breathlessness, chest pain, palpitations or blackouts, the medication you take, and any procedure or device — an implantable cardioverter defibrillator, for instance — put in place to manage risk.

None of that is shielded from an insurer, because none of it is a DNA result. It is the everyday substance of medical history. Answering questions about it accurately is simply taking reasonable care with the application, and it is what keeps a future claim from being reopened. Trying to keep a known diagnosis off the form would not be protected by the genetics rules and would put the policy itself at risk.

It is worth being clear that this is not unique to HCM. Any inherited condition that declares itself through symptoms, scans or blood tests becomes ordinary medical history at that point. The protection was never meant to hide an established diagnosis; it was meant to stop a healthy person being underwritten on a prediction. That distinction is easiest to see in the relatives around a diagnosed case, which is where we turn next.

The gene test behind the same diagnosis

HCM is often caused by an inherited fault in one of the genes that build heart muscle, and when a fault is found in a family, relatives can be offered a genetic test for that specific variant. This is where the Code does its work. A predictive genetic test — one taken by a person who does not currently have the condition, to see whether they carry the family's fault — produces a result an insurer cannot ask for or use.

For the person already diagnosed on a scan, the gene result changes little in practice: the insurer is working from the diagnosis it can already see, and it does not need the DNA test to establish something the echo has established. The confirmatory gene test sits alongside the diagnosis rather than adding a risk the insurer did not already know about. So the DNA result stays outside what an insurer requires, while the diagnosis it accompanies does the underwriting work.

Timing occasionally complicates this — for example where a test is taken after a policy is already in force. If that is your situation, our guide on having a genetic test after the policy started deals with it directly. The short version is that a predictive result taken later does not reach back into cover already granted.

Why the split is not pointless — it protects relatives

If a diagnosis can always be used, it is fair to ask what the genetic protection is even for. The answer is the relatives. When HCM is found in a family, first-degree relatives are offered cascade screening — a clinical check by ECG and echo, and often a predictive gene test for the family's variant. A great many of those relatives turn out to carry the variant while having a completely normal heart on scanning.

That person — gene-positive, scan-normal — is precisely who the Code protects. Their predictive genetic result cannot be asked for, so they are not underwritten as though they already had hypertrophic cardiomyopathy when they do not. Their scans, which are normal, tell the true story; their gene result, which merely flags a possibility, stays out of it. The protection covers risk, not established disease, and this is the case it was written for.

It is a genuinely reassuring position for a screened relative. Being tested and found to carry the variant, while your heart looks structurally normal, is not something that has to sit heavily on a future application. An ECG or echo done as part of the same screening is ordinary evidence and, if normal, says something helpful; the predictive gene result behind it is not askable at all.

How a diagnosed condition is looked at on an application

Where there is a diagnosis, an insurer will usually want detail: when it was found, your symptoms and their severity, your medication, whether a device has been fitted, and how you are followed up. It may ask for a report from your cardiologist or GP with your consent. Family history questions may also appear, and it helps to know how far back the family history question reaches before you answer them.

How all of that is weighed differs between insurers, and this is important: no page can promise you a particular decision, because it turns on the specifics and on each company's own assessment. What usually happens is that a well-documented, well-managed diagnosis is assessed on its merits, and outcomes vary from one insurer to another for the same facts. That variation is the reason to compare rather than accept the first answer. Other named conditions behave the same way — the familial high cholesterol that runs in some families is likewise assessed on its detail rather than dismissed on its label.

Because the picture is individual, the sensible step is to let someone put your actual detail to the right insurers. You can get life insurance quotes and have an FCA-authorised broker present a diagnosed or screened heart condition to the companies most comfortable with it, rather than guessing at how it will land. A cardiac event of any kind tends to prompt careful questions — the way, for example, a transient ischaemic attack is treated as evidence rather than waved through — and having it framed properly matters.

The one genetic result an insurer can ask for

For completeness, there is a single exception to the rule that predictive results stay out of underwriting, and HCM is not part of it. Under the Code, the only predictive genetic result an insurer may ask for is a test for Huntington's disease, and only where the total life cover applied for is above £500,000.

Source: HM Government and the Association of British Insurers, Code on Genetic Testing and Insurance.

Two things follow. First, no inherited heart condition — HCM included — is on that list, so a predictive gene test for a cardiomyopathy variant is never askable, at any level of cover. Second, the £500,000 threshold for Huntington's is measured across the cover you hold in total, not policy by policy, which our guide on how the £500,000 limit aggregates across every policy you hold explains, alongside what to sort out first when a parent's Huntington's puts you at risk. Those pages matter only if Huntington's is your situation; for an inherited heart condition, the exception simply does not reach you.

Where these rules apply across the UK

The insurance rules here are UK-wide. The Code on Genetic Testing and Insurance and the Consumer Insurance (Disclosure and Representations) Act 2012 — the law that sets the reasonable-care standard for answering questions — apply the same way in England, Wales, Scotland and Northern Ireland, because insurance is regulated at UK level. Whether an echo result can be used, and whether a predictive gene result can be asked for, does not change with where you live.

What is run separately is the clinical side. Inherited cardiac conditions services, cascade screening and genetic testing are delivered through NHS England, NHS Scotland, NHS Wales and Health and Social Care in Northern Ireland, so the route to an assessment and the local arrangements differ even though the underlying medicine and the insurance rules are the same. For the wider picture of how inherited risk and the numbers behind it fit together, our guide to family history, inherited risk and the odds sets out the landscape.

Frequently asked questions

Is an echocardiogram a genetic test?

No. The Code on Genetic Testing and Insurance covers tests that examine DNA, and it expressly excludes investigations such as ECGs, scans and blood tests, even when they are used to detect an inherited condition. An echo showing hypertrophic cardiomyopathy is ordinary medical evidence rather than a protected genetic result.

So can an insurer use my HCM diagnosis?

Yes, if you are asked about your heart health or a GP report is obtained with your consent. The diagnosis, the scan findings, any symptoms, medication or device fitted are all disclosable. The predictive DNA test that identified the gene behind it stays outside what an insurer may request, but the diagnosis itself does the underwriting.

Does that make the genetic protection pointless?

Not at all. It matters most for relatives who are tested but have a structurally normal heart on scanning. Their predictive gene result cannot be asked for, so they are not underwritten as though they already had the condition. The protection covers risk, not established disease.